Opdivo Secures India Patent, Fends Off Multi-Party Opposition
Useful Indicator Of Interpretation?
India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."
You may also be interested in...
An IQVIA executive in Asia sees scope for India to figure routinely on the radar of sponsors for immuno-oncology trials and outlines how some gaps to get there can be plugged.
Merck has launched Keytruda at an “India-specific” price but some experts say that the immuno-oncology therapy will likely still be beyond the reach of a majority of patients. Merck though also expects to offer a patient access program for those who can’t afford the therapy.
Bristol-Myers Squibb has taken a beating over setbacks for its Opdivo and its immuno-oncology portfolio, but a settlement reached with Merck over Keytruda’s patent infringement is a momentary victory for the PD-1 pioneer.